The Medical Letter on Drugs and Therapeutics
Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved crizotinib (Xalkori – Pfizer), an oral tyrosine kinase inhibitor, for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK) translocation, which is found in about 4-5% of lung cancers. A diagnostic test (Vysis ALK Break Apart FISH Probe Kit – Abbott Molecular) is available to detect translocations of the ALK gene in tumor samples; these translocations occur predominantly in nonsmokers with adenocarcinoma.

MECHANISM OF ACTION — Translocations of ALK, a receptor tyrosine kinase, result in expression of oncogenic fusion proteins, which increase cell proliferation. Crizotinib inhibits ALK and other receptor tyrosine kinases.

CLINICAL STUDIES — In a single-arm trial (PROFILE 1005) available only as an abstract, treatment with crizotinib 250 mg twice daily, administered continuously in 3-week ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Crizotinib (Xalkori) for Non-Small Cell Lung Cancer
Article code: 1383c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian